Send to:

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2012 Aug 1;22(15):4955-61. doi: 10.1016/j.bmcl.2012.06.038. Epub 2012 Jun 19.

Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor.

Author information

  • 1iTherX Pharmaceuticals, Inc., San Diego, CA 92191-0530, USA.


The manuscript reports an identification of a highly potent, orally bioavailable hepatitis C virus entry inhibitor through optimization of a previously reported class of molecules (1) that were not stable in the rat plasma. Compound 39 (ITX 4520) exhibited an excellent PK profile in both rats and dogs with good oral exposure, half-life and oral bioavailability. The compound is also well-tolerated in the preliminary in vivo toxicity studies and has been selected as a pre-clinical candidate for our HCV clinical pipeline.

Copyright © 2012 Elsevier Ltd. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk